Merck Says Keytruda/Chemo Combo Improved Overall Survival Compared To Chemo Alone In Gastric Cancer Settings
Merck & Co Inc (NYSE:MRK) announced results from the pivotal Phase 3 KEYNOTE-859 trial of Keytruda (pembrolizumab) with fluoropyrimidine- and platinum-containing…